A scientific statement regarding heart failure prevention in cardiovascular medicine has been published by the HFSA and ASPC.

There is decreased risk for clinical events among high-risk patients with CVD who have higher educational attainment level.

With 10 Hotline sessions, and 42 late-breaking science sessions, there is no shortage of new data for the practicing ...

Beta blockers—drugs commonly prescribed for a range of cardiac conditions, including heart attacks—provide no clinical benefit for patients who have ...

Stony Brook University Hospital (SBUH) has once again been recognized by the American Heart Association for its commitment to ...

While it is more common in older adults, it can also affect seemingly healthy young people, including athletes and students ...

Hypokalemia and even low-normal plasma potassium levels increase the risk of ventricular arrhythmias among patients with cardiovascular disease. An assessment of a strategy of actively increasing ...

Doctors at KMC Hospital diagnosed a ventricular septal rupture after an angioplasty. A surgical team led by Dr. Harish ...

Equal representation revealed important data. About 13% of men in the study had experienced a life-threatening heart rhythm ...

Features of each LVAD may be different depending on the manufacturer. Talk to your clinician about which LVAD might be right for you. Note: An LVAD is a type of VAD. VADs can support the left ...

Heart failure affects over 64 million adults globally, with a population prevalence expected to rise dramatically in the coming decades.1 Despite the availability of medical therapies that improve ...

The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...